The company's proprietary H-Guard™ technology is an anti-inflammatory treatment that suppresses the blood's foreign body response, helping dialysis to take place undetected by the body's immune system. This technology may also be used with other devices or treatments, preventing a repetitive, hostile inflammatory reaction that increases the risk of cardiovascular complications. Invizius is a spin-out based on research from the University of Edinburgh, Scotland, and is working to improve the treatment and prognosis for dialysis patients who suffer from cardiovascular disease, the leading cause of death for these patients.